J&J targets rare maternal-fetal diseases: 'We're going for this. No one else has.' Verve halts enrollment of lead trial after grade 3 side effects, prioritizing next-up PCSK9 editor Gritstone ground down by phase 2 cancer vaccine fail, sparking race against cash to gather more data Roivant’s inflammatory med gets back on track with phase 2 eye disease data Ginkgo loads up CAR assets from Modulus, the latest in a string of deals Ipsen joins ADC race via $900M biobuck deal with Sutro, chasing same target as Merck, Boehringer Carisma lets go of 37% of staff, CAR-M candidate to stretch cash runway In major step toward the clinic, Ring’s human viral vector delivers gene therapy to eyes of mice 'One-two punch' of epigenetic cancer drugs could knock out colorectal cancer cells | 